DB
CAMP icon

Dmitry Balyasny’s CAMP4 Therapeutics CAMP Stock Holding History

Dmitry Balyasny’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.3M Sell
2,575,724
-56,713
-2% -$245K 0.01% 1003
2026
Q1 		$11.6M Buy
2,632,437
+195,537
+8% +$928K 0.02% 969
2025
Q4 		$14.9M Buy
+2,436,900
New +$10.4M 0.02% 862

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Dmitry Balyasny's CAMP Position: Q2 2026 in Review

Dmitry Balyasny reduced its CAMP4 Therapeutics (CAMP) stake by 2.2% in Q2 2026, selling an estimated $245K and leaving 2,575,724 shares worth $11.3M. The position accounts for 0.01% of the portfolio, ranked #1003.

Dmitry Balyasny first reported a position in CAMP in Q4 2025 and has held it in 3 quarters since. The position peaked at $14.9M in Q4 2025. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Dmitry Balyasny held 2,575,724 shares of CAMP4 Therapeutics worth $11.3M as of Q2 2026.
  • Dmitry Balyasny sold 56,713 CAMP4 Therapeutics shares in Q2 2026, an estimated $245K.
  • CAMP4 Therapeutics made up 0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #1003 holding.
  • Dmitry Balyasny first reported a position in CAMP4 Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Dmitry Balyasny's CAMP4 Therapeutics position peaked at $14.9M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.